Contineum Therapeutics (NASDAQ:CTNM) Given New $31.00 Price Target at Royal Bank of Canada

Contineum Therapeutics (NASDAQ:CTNM) had its price target trimmed by Royal Bank of Canada from $32.00 to $31.00 in a report published on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other brokerages have also commented on CTNM. Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Robert W. Baird started coverage on shares of Contineum Therapeutics in a research note on Tuesday, October 22nd. They issued an “outperform” rating and a $32.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $29.25.

Contineum Therapeutics Trading Down 0.8 %

NASDAQ:CTNM opened at $18.40 on Thursday. Contineum Therapeutics has a 52 week low of $13.27 and a 52 week high of $22.00. The company has a fifty day moving average of $17.58 and a 200 day moving average of $17.78.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. On average, sell-side analysts predict that Contineum Therapeutics will post -2.04 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Sandia Investment Management LP bought a new position in shares of Contineum Therapeutics in the 2nd quarter worth about $88,000. Rhumbline Advisers purchased a new stake in Contineum Therapeutics during the 2nd quarter valued at about $118,000. Bank of New York Mellon Corp purchased a new stake in Contineum Therapeutics during the 2nd quarter valued at about $356,000. Driehaus Capital Management LLC purchased a new stake in Contineum Therapeutics during the 2nd quarter valued at about $1,174,000. Finally, Squarepoint Ops LLC purchased a new stake in Contineum Therapeutics during the 2nd quarter valued at about $2,642,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).